Pemigatinib for metastatic or surgically unresectable urothelial carcinoma with FGF/FGFR genomic alterations: final results from FIGHT-201

A. Necchi*, D. Pouessel, R. Leibowitz, S. Gupta, A. Fléchon, J. García-Donas, M. A. Bilen, P. R. Debruyne, M. I. Milowsky, T. Friedlander, M. Maio, A. Gilmartin, X. Li, M. L. Veronese, Y. Loriot*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

8 Scopus citations

Fingerprint

Dive into the research topics of 'Pemigatinib for metastatic or surgically unresectable urothelial carcinoma with FGF/FGFR genomic alterations: final results from FIGHT-201'. Together they form a unique fingerprint.

Keyphrases

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science